Effects of XT-44, a Phosphodiesterase 4 Inhibitor, in Osteoblastgenesis and Osteoclastgenesis in Culture and Its Therapeutic Effects
-
- Waki Yoshihiro
- Department of Pharmacology, Faculty of Dentistry, Tokyo Medical and Dental University Department of Pharmacology and Pharmaceutics, Graduate School of Natural Science & Technology, Kanazawa University
-
- Horita Takashi
- Department of Pharmacology and Pharmaceutics, Graduate School of Natural Science & Technology, Kanazawa University
-
- Miyamoto Ken-ichi
- Department of Pharmacology and Pharmaceutics, Graduate School of Natural Science & Technology, Kanazawa University
-
- Ohya Keiichi
- Department of Pharmacology, Faculty of Dentistry, Tokyo Medical and Dental University
-
- Kasugai Shohei
- Department of Pharmacology, Faculty of Dentistry, Tokyo Medical and Dental University
Bibliographic Information
- Other Title
-
- Effects of XT-44,a Phosphodiesterase 4 Inhibitor,in Osteoblastgenesis and Osteoclastgenesis in Culture and Its Therapeutic Effects in Rat Osteopenia Models
Search this article
Abstract
We have reported that denbufylline, a phosphodiesterase 4 (PDE4) inhibitor, inhibits bone loss in Walker256/S tumor-bearing rats, suggesting therapeutic potentiality of a PDE4 inhibitor in osteopenia. In the present study, effects of a new PDE4 inhibitor, 1-n-butyl-3-n-propylxanthine (XT-44), in bone were evaluated in cell cultures and animal experiments. In rat bone marrow culture, XT-44 stimulated mineralized-nodule formation, whereas it inhibited osteoclast-like cell formation in mouse bone marrow culture. In Walker256/S-bearing rats (6-week-old female Wistar Imamichi rats), rapid decrease in bone mineral density (BMD) was prominent, and oral administration of XT-44 (0.3 mg/kg, every 2 days) inhibited the decrease in BMD. In the second animal experiment, female Wistar rats (6-week-old) were sciatic neurectomized, and XT-44 was orally administered to these rats every 2 days for 4 weeks. XT-44 administration (0.3 mg/kg) recovered BMD in these neurectomized animals. Furthermore, 19-week-old, female Wistar rats were ovariectomized (OVX), and 15 weeks after surgery, these rats were orally administered XT-44 every 2 days for 8 weeks. XT-44 treatment (1 mg/kg) increased the BMD of OVX rats. These results indicate that XT-44 could be a candidate as a therapeutic drug for treating osteopenia including osteoporosis.
Journal
-
- The Japanese Journal of Pharmacology
-
The Japanese Journal of Pharmacology 79 (4), 477-483, 1999
The Japanese Pharmacological Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679264128128
-
- NII Article ID
- 10008683591
-
- NII Book ID
- AA00691188
-
- COI
- 1:CAS:528:DyaK1MXislejur8%3D
-
- ISSN
- 13473506
- 00215198
-
- NDL BIB ID
- 4706164
-
- PubMed
- 10361888
-
- Web Site
- https://ndlsearch.ndl.go.jp/books/R000000004-I4706164
- https://api.elsevier.com/content/article/PII:S0021519819309308?httpAccept=text/xml
- https://api.elsevier.com/content/article/PII:S0021519819309308?httpAccept=text/plain
- https://www.jstage.jst.go.jp/article/jjp/79/4/79_4_477/_pdf
- https://search.jamas.or.jp/link/ui/1999211500
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed